Sai Life Sciences IPO
IPO Details
- Open Date
11 Dec 2024
- Close Date
13 Dec 2024
- IPO
Price Range
₹ 522 - ₹ 549
- IPO
Size
₹ 3042.62 Cr
- Listing Exchange
BSE, NSE
- Listing Date
18 Dec 2024
IPO Timeline
Sai Life Sciences IPO Subscription Status
| Date | QIB | NII | Retail | TOTAL |
|---|---|---|---|---|
| 11-Dec-24 | 2.52 | 0.16 | 0.19 | 0.85 |
| 12-Dec-24 | 3.20 | 0.60 | 0.43 | 1.26 |
| 13-Dec-24 | 29.78 | 4.99 | 1.39 | 10.27 |
Last Updated: 13 December 2024 6:01 PM by 5Paisa
Sai Life Sciences IPO opens for subscription on December 11, 2024 and closes on December 13, 2024. The company offers tailor-made services to biotech firms and global pharma companies.
Sai Life Sciences IPO price band is set at ₹522 to ₹549 per share. The minimum lot size for an application is 27 Shares. The minimum amount of investment required by retail investors is ₹14,094.
Kotak Mahindra Capital Company Limited, Jefferies India Private Limited, Morgan Stanley India Company Pvt Ltd, and Iifl Securities Ltd are the book-running lead managers of the Sai Life Sciences IPO, while Kfin Technologies Limited is the registrar for the issue.
Sai Life Sciences IPO Size
| Types | Size |
|---|---|
| Total IPO Size | ₹ 3,042.62 Cr |
| Offer For Sale | ₹ 950.00 |
| Fresh Issue | ₹2,092.62 Cr |
Sai Life Sciences IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 27 | ₹14,094 |
| Retail (Max) | 13 | 351 | ₹183,222 |
| S-HNI (Min) | 14 | 378 | ₹197,316 |
| S-HNI (Max) | 67 | 1,809 | ₹944,298 |
| B-HNI (Min) | 68 | 1,836 | ₹958,392 |
Sai Life Sciences IPO Reservation
| Investors Category | Subscription (times) | Shares Offered | Shares bid for | Total Amount (Cr.) |
|---|---|---|---|---|
| QIB | 29.78 | 1,10,84,225 | 33,01,25,058 | 18,123.866 |
| NII (HNI) | 4.99 | 83,13,168 | 4,15,22,058 | 2,279.561 |
| Retail | 1.39 | 1,93,97,392 | 2,69,12,574 | 1,477.500 |
| Total | 10.27 | 3,87,94,785 | 39,85,59,690 | 21,880.927 |
Sai Life Sciences IPO Anchor Allocation
| Anchor Bid Date | 10 December, 2024 |
| Shares Offered | 16,626,336 |
| Anchor portion Size (In ₹ Cr.) | 912.79 |
| Anchor lock-in period end date for 50% shares (30 Days) | 15 January, 2024 |
| Anchor lock-in period end date for remaining shares (90 Days) | 16 March, 2024 |
1. Repayment/prepayment in full or part, of all or certain outstanding borrowings availed by the Company and
2. General corporate purposes
Incorporated in January 1999, Sai Life Sciences Limited researches, develops, and manufactures small-molecule new chemical entities. The company offers tailor-made services to biotech firms and global pharma companies.
In the Financial Year 2024 and for the month ending September 30, 2024, the company provided services to over 280 innovator pharmaceutical companies, including more than 230 in that month alone. Among these clients, the company worked with 18 of the top 25 pharmaceutical companies based on their revenue in the calendar year 2023. The services were offered across countries such as the US, the UK, Europe, and Japan.
The company's business development team consists of 16 experienced and qualified professionals, with six located in the US, nine in the UK and Europe, and one in Japan.
The company has the following service offerings:
Capabilities in chemistry, manufacturing, and control(“CMC”)/contract development and manufacturing organizations (“CDMO”).
CRO services include integrated discovery (“Discovery”) capabilities across biology, chemistry, drug metabolism, and pharmacokinetics.
Peers
DIVI'S LABORATORIES Limited
Suven Pharmaceuticals Limited
Syngene International Ltd.
| Particulars (in Rs. Crores) | FY24 | FY23 | FY22 |
|---|---|---|---|
| Revenue | 1,494.27 | 1,245.11 | 897.74 |
| EBITDA | 300 | 182.2 | 131.0 |
| PAT | 82.81 | 9.99 | 6.23 |
| Particulars (in Rs. Crores) | FY24 | FY23 | FY22 |
|---|---|---|---|
| Total Assets | 2,275.14 | 2,186.65 | 2,164.23 |
| Share Capital | 18.1 | 18.0 | 17.9 |
| Total Borrowings | 710.16 | 699.23 | 751.32 |
| Particulars (in Rs. Crores) | FY24 | FY23 | FY22 |
|---|---|---|---|
| Net Cash Generated From / (used in) operating activities | 263 | 219.4 | 104.9 |
| Net Cash Generated From / (used in) investing activities | -192.4 | -101.8 | -103.7 |
| Net Cash Generated From / (used in) financing activities | -95.3 | -200.6 | 71.9 |
| Net Increase (Decrease) In Cash And Cash Equivalents | -25 | -83 | 73 |
Strengths
1. As an integrated CRDMO, the company provides a complete platform for discovery, development, and manufacturing.
2. CRO services include integrated discovery capabilities across biology, chemistry, drug metabolism, and pharmacokinetics.
3. CDMO platform with a diverse mix of commercial and under-development molecules.
Risks
1. Excess Production Capacity and Associated Costs.
2. Need for Experienced and Skilled Workforce.
3. Regulatory Compliance Risks.
in 3
easy steps
Using 5paisa App or
Website
to block Payment
Open Free Demat Account
Be a part of 5paisa community - The first listed discount broker of India.
By proceeding, you agree to all T&C*
FAQs
Sai Life Sciences IPO opens from 11 December to 13 December 2024.
The size of Sai Life Sciences IPO is ₹3,042.62 Cr.
The price of Sai Life Sciences IPO is fixed at ₹522 to ₹549 per share.
To apply for Sai Life Sciences IPO, follow the steps given below:
● Login to your 5paisa account and select the issue in the current IPO section
● Enter the number of lots and the price at which you wish to apply for the Sai Life Sciences IPO.
● Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.
You will receive a mandate notification to block funds in your UPI app.
The minimum lot size of Sai Life Sciences IPO is 27 shares and the investment required is ₹14,094.
The share allotment date of Sai Life Sciences IPO is December 16, 2024.
The Sai Life Sciences IPO will be listed on December 18, 2024.
Kotak Mahindra Capital Company Limited, Jefferies India Private Limited, Morgan Stanley India Company Pvt Ltd and Iifl Securities Ltd are the book running lead managers of the Sai Life Sciences IPO.
Sai Life Sciences plans to utilize the raised capital from the IPO for:
1. Repayment/prepayment in full or part, of all or certain outstanding borrowings availed by the Company and,
2. General corporate purposes.
Contact Information
Sai Life Sciences
Sai Life Sciences Limited
Plot No. DS-7, IKP Knowledge Park
Turkapally Village, Shameerpet Mandal,
Malkajgiri District, Hyderabad-500078
Phone: +9140 6815 6000
Email: investors@sailife.com
Website: https://www.sailife.com/
Sai Life Sciences IPO Register
Kfin Technologies Limited
Phone: 04067162222, 04079611000
Email: sailifesciences.ipo@kfintech.com
Website: https://kosmic.kfintech.com/ipostatus/
Sai Life Sciences IPO Lead Manager
Kotak Mahindra Capital Company Limited
Jefferies India Private Limited
Morgan Stanley India Company Pvt Ltd
Iifl Securities Ltd
